Publication date: Nov 01, 2023
Traditional Chinese medicines (TCM) play an indispensable role during the pandemic of coronavirus disease 2019 (COVID-19), with an increasing number of randomized controlled trials (RCTs) designed and performed to evaluate the efficacy and safety of TCM for COVID-19. This study aimed to critically appraise the quality of currently available RCTs of TCM for COVID-19. RCTs of TCM for COVID-19 were searched from three databases by two investigators and selected according to pre-established inclusion and exclusion criteria. General information of included studies was presented by applying descriptive statistics. The methodological and reporting quality of eligible RCTs was critically evaluated based on the risk of bias assessment tool 2 (RoB2) and CONSORT Extension for TCM (CONSORT-CHM Formulas 2017), respectively. The differences of risks and main general information were compared between RCTs published in English and Chinese journals. Microsoft Excel 2019 and SPSS were used for the statistical analysis. A result with p
| Concepts | Keywords |
|---|---|
| Chinese | COVID-19 |
| Coronavirus | Quality appraisal |
| Methodological | Randomized controlled trials |
| Microsoft | Traditional Chinese medicines |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | quality |
| disease | MESH | coronavirus disease 2019 |